# US 2010/0144695 A1 · 4-azetidinyl-1-heteroaryl-cyclohexanol antagonists of ccr2

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0144695 A1
- Document ID: US20100144695A1
- Status: Published application
- Kind: A1
- Application number: 12/633,861
- Filed: 2009-12-09
- Published: 2010-06-10
- Earliest claimed: 2008-12-10
- Assignees: Janssen Pharmaceutica NV
- Inventors: Xuqing Zhang; Heather Rae Hufnagel; Cuifen Hou; Dana L. Johnson; Zhihua Sui; Barry Fegely; David Breslin
- Web page: https://patentgrep.com/patent/US20100144695A1

## CPC

- C07D 401/08: linked by a carbon chain containing alicyclic rings
- A61P 1/02: Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A61P 1/04: for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 7/12: Antidiuretics, e.g. drugs for diabetes insipidus (ADH A61P5/10)
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 11/02: Nasal agents, e.g. decongestants
- A61P 11/06: Antiasthmatics
- A61P 13/08: of the prostate
- A61P 13/10: of the bladder
- A61P 13/12: of the kidneys
- A61P 15/00: Drugs for genital or sexual disorders (for disorders of sex hormones A61P5/24); Contraceptives
- A61P 17/00: Drugs for dermatological disorders
- A61P 17/04: Antipruritics
- A61P 17/06: Antipsoriatics
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 37/08: Antiallergic agents (antiasthmatic agents A61P11/06; ophthalmic antiallergics A61P27/14)
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 403/08: linked by a carbon chain containing alicyclic rings
- C07D 407/14: containing three or more hetero rings
- C07D 409/08: linked by a carbon chain containing alicyclic rings
- C07D 413/08: linked by a carbon chain containing alicyclic rings
- C07D 417/08: linked by a carbon chain containing alicyclic rings
- C07D 417/14: containing three or more hetero rings
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention comprises compounds of Formula (I). wherein: R1, R2, R3, and R4 are as defined in the specification. The invention also comprises pharmaceutical compositions comprising the compounds of formula (I) and methods of preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease, for example, type II diabetes, obesity or asthma, by administering the compounds of formula (I).

## Claims

### Claim 1

A compound of Formula (I)
wherein:
R1 is
pyridyl, pyridyl-N-oxide, 1H-pyridin-2-onyl, indolyl, pyrazinyl, 3-H-thiazol-2-onyl, pyrimidyl, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, thiophenyl, furyl, [1,2,4]oxadiazolyl or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, pyrimidyl, pyrazolyl, imidazolyl, thiophenyl, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, CHCN, C(1-4)alkyl, CH2CF3, N(C(1-4)alky1)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, CO2H, CONH2, NHCO2C(1-4)alkyl, N(SO2CH3)2, NHSO2CH3, NHC(O)CF3, NHC(1-4)alkyl, NHCO2H, NHCO2C(1-4)alkyl, NHCOC(1-4)alkyl, NHCONH2, NHCONHC(1-4)alkyl, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; or wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; or wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, or wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3; or wherein said 1H-pyridin-2-onyl is optionally substituted with one substituent selected from the group consisting of CH2CN, C(1-4)alkyl, CH2CF3, and CH2CH2OH, or said 1H-pyridin-2-onyl may be optionally substituted with up to 2 methyl groups; or wherein said [1,2,4]oxadiazolyl is optionally substituted on any carbon atom with CCl3, or pyrrolidinyl, or alternatively both hydrogens on said carbon atom of said [1,2,4]oxadiazolyl may be replaced by an oxo group;
R2 is C(1-4)alkyl, NH2, NO2, NHCH2CH2OH, N(C(1-4)alkyl)2, N(SO2CH3)2, CN, F, Cl, Br, CF3, C(3-6)cycloalkyl, heterocyclyl, OCF3, OCF2H, CF2H, or OC(1-4)alkyl;
R3 is H, F, Cl, CF3, or OC(1-4)alkyl; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, or 2,3-dihydro-benzo[1,4]dioxinyl group;
R4 is H, OC(1-4)alkyl, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 2 (depends on 1)

A compound claim 1 wherein:
R1 is
pyridyl, pyridyl-N-oxide, 1H-pyridin-2-onyl, indolyl, pyrazinyl, 3-H-thiazol-2-onyl, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, [1,2,4]oxadiazolyl or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, CH2CN, C(1-4)alkyl, CH2CF3, N(C(1-4)alkyl)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, CO2H, CONH2, NHCO2C(1-4)alkyl, N(SO2CH3)2, NHSO2CH3, NHC(O)CH3, NHC(O)CF3, NHC(1-4)alkyl, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3; wherein said 1H-pyridin-2-onyl is optionally substituted with one substituent selected from the group consisting of CH2CN, C(1-4)alkyl, CH2CF3, and CH2CH2OH, or said 1H-pyridin-2-onyl may be optionally substituted with up to 2 methyl groups; wherein said [1,2,4]oxadiazolyl is optionally substituted on any carbon atom with CCl3, or pyrrolidinyl, or alternatively both hydrogens on said carbon atom of said [1,2,4]oxadiazolyl may be replaced by an oxo group;
R2 is C(1-4)alkyl, NH2, NO2, NHCH2CH2OH, N(C(1-4)alkyl)2, N(SO2CH3), CN, F, Cl, Br, CF3, pyrrolidinyl, OCF3, OCF2H, CF2H, or OC(1-4)alkyl;
R3 is H, F, Cl, CF3, or OC(1-4)alkyl; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, OCH3, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 3 (depends on 2)

A compound claim 2 wherein:
R1 is pyridyl, pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, C(1-4)alkyl, N(C(1-4)alkyl)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3;
R2 is NH2, NO2, NHCH2CH2OH, N(CH3)2, N(SO2CH3)2, CN, F, Cl, Br, CF3, pyrrolidinyl, or OCH3;
R3 is H, F, Cl, CF3, or OCH3; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 4 (depends on 3)

A compound claim 3 wherein:
R1 is pyridyl, pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3,4]thiadiazolyl; wherein said pyridyl or pyridyl-N-oxide is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, C(1-4)alkyl, N(C(1-4)alkyl)2, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted with C(1-4)alkyl, CH2OH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, OH NH2, N(C(1-4)alkyl)2, pyrrolidinyl, OC(1-4)alkyl, NHCN, or said thiazolyl may be substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 5 (depends on 4)

A compound claim 4 wherein:
R1 is pyridyl, methoxy substituted pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3,4]thiadiazolyl; wherein said pyridyl is optionally substituted with one substituent selected from the group consisting of OCH3, OCH2CH3, OCH(CH3)2, OC(CH3)3, cyclobutoxy, OCH2CF3, OCH2Ph, F, CN, CH3, N(CH3)2, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(CH3)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted with CH2OH, Si(CH3)3, CH3, CH2CH3, CH(CH3)2, —C≡CH, SCH3, S(O)CH3, SO2CH3, OH, NH2, N(CH3)2, pyrrolidinyl, OCH3, OCH(CH3)2, NHCN, or said thiazolyl may be substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br;
R2 is CF3, F, Cl, CN, or OCH3,
R3 is H, F, Cl, or CF3, alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 6 (depends on 1)

A compound of claim 1 selected from the group consisting of:
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 7 (depends on 6)

A compound of claim 6 selected from the group consisting of:
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof

### Claim 8

A compound of the formula
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 9

A compound of Formula (Ia)
wherein:
R1 is
pyridyl, pyridyl-N-oxide, 1H-pyridin-2-onyl, indolyl, pyrazinyl, 3-H-thiazol-2-onyl, pyrimidyl, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, pyrazolyl, imidazolyl, thiophenyl, furyl, [1,2,4]oxadiazolyl or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, pyrimidyl, pyrazolyl, imidazolyl, thiophenyl, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, CH2CN, C(1-4)alkyl, CH2CF3, N(C(1-4)alkyl)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, CO2H, CONH2, NHCO2C(1-4)alkyl, N(SO2CH3)2, NHSO2CH3, NHC(O)CF3, NHC(1-4)alkyl, NHCO2H, NHCO2C(1-4)alkyl, NHCOC(1-4)alkyl, NHCONH2, NHCONHC(1-4)alkyl, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; or wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; or wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, or wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3; or wherein said 1H-pyridin-2-onyl is optionally substituted with one substituent selected from the group consisting of CH2CN, C(1-4)alkyl, CH2CF3, and CH2CH2OH, or said 1H-pyridin-2-onyl may be optionally substituted with up to 2 methyl groups; or wherein said [1,2,4]oxadiazolyl is optionally substituted on any carbon atom with CCl3, or pyrrolidinyl, or alternatively both hydrogens on said carbon atom of said [1,2,4]oxadiazolyl may be replaced by an oxo group;
R2 is C(1-4)alkyl, NH2, NO2, NHCH2CH2OH, N(C(1-4)alkyl)2, N(SO2CH32, CN, F, Cl, Br, CF3, C(3-6)ocycloalkyl, heterocyclyl, OCF3, OCF2H, CF2H, or OC(1-4)alkyl;
R3 is H, F, Cl, CF3, or OC(1-4)alkyl; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl, 2,3-dihydro-benzofuranyl, or 2,3-dihydro-benzo[1,4]dioxinyl group;
R4 is H, OC(1-4)alkyl, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 10 (depends on 9)

A compound claim 9 wherein:
R1 is
pyridyl, pyridyl-N-oxide, 1H-pyridin-2-onyl, indolyl, pyrazinyl, 3-H-thiazol-2-onyl, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, [1,2,4]oxadiazolyl or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, CH2CN, C(1-4)alkyl, CH2CF3, N(C(1-4)alkyl)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, CO2H, CONH2, NHCO2C(1-4)alkyl, N(SO2CH3)2, NHSO2CH3, NHC(O)CH3, NHC(O)CF3, NHC(1-4)alkyl, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3; wherein said 1H-pyridin-2-onyl is optionally substituted with one substituent selected from the group consisting of CH2CN, C(1-4)alkyl, CH2CF3, and CH2CH2OH, or said 1H-pyridin-2-onyl may be optionally substituted with up to 2 methyl groups; wherein said [1,2,4]oxadiazolyl is optionally substituted on any carbon atom with CCl3, or pyrrolidinyl, or alternatively both hydrogens on said carbon atom of said [1,2,4]oxadiazolyl may be replaced by an oxo group;
R2 is C(1-4)alkyl, NH2, NO2, NHCH2CH2OH, N(C(1-4)alkyl)2, N(SO2CH3)2, CN, F, Cl, Br, CF3, pyrrolidinyl, OCF3, OCF2H, CF2H, or OC(1-4)alkyl;
R3 is H, F, Cl, CF3, or OC(1-4)alkyl; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, OCH3, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 11 (depends on 10)

A compound claim 10 wherein:
R1 is pyridyl, pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3,4]thiadiazolyl; wherein said pyridyl, pyridyl-N-oxide, or thiazolyl is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, C(1-4)alkyl, N(C(1-4)alkyl)2, C(1-4)alkylOH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, pyrrolidinyl, OH, NH2, NHCN, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br or OCH3;
R2 is NH2, NO2, NHCH2CH2OH, N(CH3)2, N(SO2CH3)2, CN, F, Cl, Br, CF3, pyrrolidinyl, or OCH3;
R3 is H, F, Cl, CF3, or OCH3; alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 12 (depends on 11)

A compound claim 11 wherein:
R1 is pyridyl, pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3, 4]thiadiazolyl; wherein said pyridyl or pyridyl-N-oxide is optionally substituted with one substituent selected from the group consisting of OC(1-4)alkyl, OC(3-6)cycloalkyl, OCH2CF3, OCH2Ph, F, CN, C(1-4)alkyl, N(C(1-4)alkyl)2, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(C(1-4)alkyl)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted with C(1-4)alkyl, CH2OH, Si(CH3)3, —C≡CH, SCH3, S(O)CH3, SO2CH3, OH, NH2, N(C(1-4)alkyl)2, pyrrolidinyl, OC(1-4)alkyl, NHCN, or said thiazolyl may be substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 13 (depends on 12)

A compound claim 12 wherein:
R1 is pyridyl, methoxy substituted pyridyl-N-oxide, pyrimidyl, methyl substituted imidazolyl, methyl substituted pyrazolyl optionally substituted with Br, thiophenyl optionally substituted with Br, benzooxazolyl, oxazolyl, thiazolyl, isothiazolyl, or [1,3,4]thiadiazolyl; wherein said pyridyl is optionally substituted with one substituent selected from the group consisting of OCH3, OCH2CH3, OCH(CH3)2, OC(CH3)3, cyclobutoxy, OCH2CF3, OCH2Ph, F, CN, CH3, N(CH3)2, and Br; or said pyridyl may be substituted with one OCH3 group and one CH3; wherein said pyrimidyl is optionally substituted with one N(CH3)2 group or one or two OCH3 groups; wherein said thiazolyl is optionally substituted with CH2OH, Si(CH3)3, CH3, CH2CH3, CH(CH3)2, —C≡CH, SCH3, S(O)CH3, SO2CH3, OH, NH2, N(CH3)2, pyrrolidinyl, OCH3, OCH(CH3)2, NHCN, or said thiazolyl may be substituted on two adjacent carbon atoms to form fused bicyclic system benzothiazol-2-yl, wherein said benzothiazol-2-yl is optionally substituted with Br;
R2 is CF3, F, Cl, CN, or OCH3,
R3 is H, F, Cl, or CF3, alternatively, R2 and R3 may be taken together with their attached phenyl to form a benzo[1,3]dioxolyl group;
R4 is H, or F;
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 14 (depends on 9)

A compound of claim 9 selected from the group consisting of:
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 15

A compound of the formula
and solvates, hydrates, tautomers, prodrugs, and pharmaceutically acceptable salts thereof.

### Claim 16 (depends on 15)

A compound of claim 15 of the formula

### Claim 17 (depends on 16)

A crystalline compound of claim 16 having the following XRPD °2Θ peaks:
Position [°2θ]
7.0
7.4
9.3
11.0
12.6
14.3
14.4
14.8
15.3
17.1
17.4
18.3
18.7
19.2
19.7
21.3
21.8
22.2
22.9
23.5
23.9
24.5
24.7
25.3
26.3
28.2
28.8
29.5

### Claim 18 (depends on 1)

A pharmaceutical composition, comprising a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 19 (depends on 1)

A pharmaceutical composition made by mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 20 (depends on 1)

A process for making a pharmaceutical composition comprising mixing a compound of claim 1 and a pharmaceutically acceptable carrier.

### Claim 21 (depends on 9)

A pharmaceutical composition, comprising a compound of claim 9 and a pharmaceutically acceptable carrier.

### Claim 22 (depends on 9)

A pharmaceutical composition made by mixing a compound of claim 9 and a pharmaceutically acceptable carrier.

### Claim 23 (depends on 9)

A process for making a pharmaceutical composition comprising mixing a compound of claim 9 and a pharmaceutically acceptable carrier.

### Claim 24 (depends on 1)

A method for preventing, treating or ameliorating a CCR2 mediated syndrome, disorder or disease comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 25 (depends on 1)

A method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is selected from the group consisting of: chronic obstructive pulmonary disorder (COPD), ophthalmic disorders, uveitis, atherosclerosis, rheumatoid arthritis, psoriasis, psoriatic arthritis, atopic dermatitis, multiple sclerosis, Crohn's Disease, ulcerative colitis, nephritis, organ allograft rejection, fibroid lung, renal insufficiency, type-I diabetes, type II diabetes, diabetic complications, diabetic nephropathy, diabetic retinopathy, diabetic retinitis, diabetic microangiopathy, overweight, obesity, obesity-associated insulin resistance, metabolic syndrome, tuberculosis, sarcoidosis, invasive staphyloccocia, inflammation after cataract surgery, allergic rhinitis, allergic conjunctivitis, chronic urticaria, asthma, allergic asthma, periodontal diseases, periodonitis, gingivitis, gum disease, diastolic cardiomyopathies, cardiac infarction, myocarditis, chronic heart failure, angiostenosis, restenosis, reperfusion disorders, aortic abdominal aneurism, glomerulonephritis, solid tumors and cancers, chronic lymphocytic leukemia, chronic myelocytic leukemia, multiple myeloma, malignant myeloma, Hodgkin's disease, carcinomas of the bladder, breast, cervix, colon, lung, prostate, or stomach, and chronic neuroinflammatory disorders including, but not limited to, Alzheimer's disease, ischemic stroke, spinal cord injury, nerve crush injury and traumatic brain injury comprising administering to a subject in need thereof an effective amount of a compound of claim 1.

### Claim 26 (depends on 1)

A method of preventing, treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is selected from the group consisting of: type I diabetes, type II diabetes, diabetic complications, diabetic nephropathy, diabetic retinopathy, diabetic retinitis, diabetic microangiopathy, obesity, obesity-associated insulin resistance, metabolic syndrome, asthma, and allergic asthma, comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.

### Claim 27 (depends on 1)

A method of treating a disorder selected from the group consisting of type II diabetes, obesity and asthma comprising administering to a subject in need thereof a therapeutically effective amount of a compound of claim 1.
